secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0001213900-24-008888
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma prioritizes 2024 pipeline targeting PTSD, chronic pain, neurology; plans Pre-IND for SPC-15 by Q2
--------------------------------------------------------------------------------

- Lead program SPC-15 (intranasal PTSD prophylactic) Pre-IND submission planned by end of Q2 2024.
- SP-26 is a non-opioid, time-release ketamine implant for fibromyalgia, potential first at-home ketamine treatment.
- SPC-14 (Alzheimer's) positive animal results; more data expected in 2024; SPU-16 targets MS via homing peptide.
- FDA 505(b)(2) pathway to be used for SPC-15, SP-26, and SPC-14 to expedite approval and reduce costs.
- Pipeline includes four drugs across three therapeutic areas: mental health, chronic pain, and neurology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024008888/0001213900-24-008888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024008888/ea192611-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-008888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer